Interested to attend a conference to know the most recent diagnostic and therapeutic advances and treatment options in hematologic malignancies ?
Here is a wonderful opportunity !
Save the Dates !
The Moffitt Cancer Center conducting the 15th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
Conference Location: Disney’s Grand Floridian Resort, 4401 Floridian Way, Lake Buena Vista, Florida
Conference Dates: January 19th 2019
USF Health designated this live activity for a maximum of 6.00 AMA PRA Category 1 CreditsTM.
The 15th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies Conference is designed to present the most recent diagnostic and therapeutic advances and treatment options in hematologic malignancies to practicing hematologists, oncologists, pharmacists, advanced practice professionals and oncology nurses. This one-day interactive conference will cover AML, MDS, NHL, CLL and Myeloma in a format that includes plenary lectures, case presentations and discussions. Ample time will be available for networking.
Hematologic malignancies are the types of cancer that affect blood, bone marrow and lymph nodes and account for 9.5% of new cancer diagnoses in the United States. Florida is home to 3.3 million seniors and this group carries the greatest burden of cancer. It’s critical that Florida oncologists be updated on new treatment and management therapies to meet the needs of this population.
Physician competencies to be addressed:
- Identify and discuss novel treatment options available for patients with AML.
- Explain the role of transplant in patients with AML.
- Select the optimal use of the newer pharmaceutical agents in the treatment of Hodgkin’s lymphoma.
- Justify the role of molecular profiling in MDS
- Select the optimal management for patients with Philadelphia chromosome positive ALL.
- Identify the pros and cons of stem cell transplant in patients with high risk B cell non-Hodgkin’s lymphoma in first complete remission (CR).
- Describe the optimal use of novel agents in the management of patients with previously untreated CLL.
- Examine new drug therapies in the treatment of multiple myeloma.
- Describe therapeutic strategies for managing patients with myelofibrosis.
- Recognize the side effects associated with the newer agents used in the treatment of multiple myeloma and Hodgkin’s lymphoma.
Gap Analysis and Best Practice
Healthcare providers treating hematologic malignancies need to be able to identify and discuss the most up-to-date options available for their patients with AML, MDS, CLL and multiple myeloma.
When healthcare providers see their young patients with poor risk CLL, they need to be able to evaluate therapy choices and indications for the newest drugs for CLL.
Healthcare providers need to be able to recognize the processes involved and the side effects of CAR T lymphoproliferative disorders.
Healthcare providers will be able to better understand what the best treatment options are for their CLL patients.
Healthcare providers will feel more confident when providing management options for their patients with multiple myeloma who relapse after autologous stem cell transplant.
Healthcare providers will be able to evaluate the role of CAR T cell therapy when treating their patients with lymphoproliferative disorders.
- Patient Care and Procedural Skills
- Systems-Based Practice
- Medical Knowledge